ATE475713T1 - Trans-lentivirales vektor system - Google Patents

Trans-lentivirales vektor system

Info

Publication number
ATE475713T1
ATE475713T1 AT00984421T AT00984421T ATE475713T1 AT E475713 T1 ATE475713 T1 AT E475713T1 AT 00984421 T AT00984421 T AT 00984421T AT 00984421 T AT00984421 T AT 00984421T AT E475713 T1 ATE475713 T1 AT E475713T1
Authority
AT
Austria
Prior art keywords
present
dna encoding
trans
protein
lentiviral
Prior art date
Application number
AT00984421T
Other languages
English (en)
Inventor
John Kappes
Xiaoyun Wu
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE475713T1 publication Critical patent/ATE475713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00984421T 1999-12-14 2000-12-14 Trans-lentivirales vektor system ATE475713T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/460,548 US6555342B1 (en) 1998-06-03 1999-12-14 Fusion protein delivery system and uses thereof
PCT/US2000/034021 WO2001044481A1 (en) 1999-12-14 2000-12-14 Fusion protein delivery system and uses thereof

Publications (1)

Publication Number Publication Date
ATE475713T1 true ATE475713T1 (de) 2010-08-15

Family

ID=23829157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984421T ATE475713T1 (de) 1999-12-14 2000-12-14 Trans-lentivirales vektor system

Country Status (9)

Country Link
US (4) US6555342B1 (de)
EP (1) EP1244797B1 (de)
JP (1) JP4842482B2 (de)
AT (1) ATE475713T1 (de)
AU (1) AU785283B2 (de)
CA (1) CA2394261C (de)
DE (1) DE60044754D1 (de)
NZ (1) NZ519671A (de)
WO (1) WO2001044481A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449858T1 (de) * 1999-10-11 2009-12-15 Pasteur Institut Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
GB0024550D0 (de) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002070651A2 (en) * 2001-03-02 2002-09-12 Merck & Co., Inc. Viral reporter particles
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
IL161229A0 (en) 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
US20030167500A1 (en) * 2001-12-21 2003-09-04 Ram Ramabhadran Methods and compositions for generating a genetically modified animal using lentiviral vectors
US20050214945A1 (en) * 2002-05-17 2005-09-29 Eastern Virginia Medical School Htlv-I tax induced killing of p53 null cancer cells
EP2572734B1 (de) 2006-10-31 2016-04-06 East Carolina University Cytokinbasierte Fusionsproteine zur Behandlung von Immunstörungen
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
WO2010040023A2 (en) * 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
AU2010234743A1 (en) 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
EP3663395A1 (de) 2012-03-26 2020-06-10 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Verabreichung von verkapselter rna an säugerzellen
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
EP3355910A4 (de) 2015-09-28 2019-08-28 East Carolina University Auf aluminium basierte adjuvanzien für tolerogene impfung

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE275259C (de)
GB8818020D0 (en) 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
CA2056452A1 (en) 1989-06-02 1990-12-03 William A. Haseltine Protein having a transactivating property, vectors expressing this protein, cell lines, and uses thereof
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0491930B1 (de) 1990-07-12 1997-01-15 The President And Fellows Of Harvard College Primaten-lentivirus impfstoffe
CA2135618A1 (en) 1992-05-22 1993-09-12 Joseph Sodroski Vectors expressing hybrid viruses, methods of use and novel assays
WO1993025235A1 (en) 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
AU5848794A (en) 1993-02-05 1994-08-29 Regents Of The University Of California, The Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU1373395A (en) 1993-12-15 1995-07-03 Trustees Of The University Of Pennsylvania, The Vpr receptor protein
CA2186398A1 (en) 1994-03-25 1995-10-05 Ahmed A. Azad Vpr and vpx proteins of hiv
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5639619A (en) 1994-10-13 1997-06-17 Regents Of The University Of California Screening assay for anti-HIV drugs using the Vpr gene
DE69637677D1 (de) * 1995-04-14 2008-10-23 Univ Alabama Res Found Transfer system basierend auf einem fusionsprotein und seine anwendungen.
US6200811B1 (en) 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
EP0991771A2 (de) * 1997-03-06 2000-04-12 Klaus Überla Vektoren, die auf lentiviren basieren und vektorsysteme
AU3988799A (en) 1998-05-13 1999-11-29 Genetix Pharmaceuticals, Inc. Novel lentiviral packaging cells
EP1141313A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln

Also Published As

Publication number Publication date
EP1244797A4 (de) 2004-07-28
EP1244797B1 (de) 2010-07-28
CA2394261C (en) 2012-09-04
DE60044754D1 (de) 2010-09-09
CA2394261A1 (en) 2001-06-21
US20080233639A1 (en) 2008-09-25
US7259014B2 (en) 2007-08-21
WO2001044481A1 (en) 2001-06-21
EP1244797A1 (de) 2002-10-02
US20050014260A1 (en) 2005-01-20
JP4842482B2 (ja) 2011-12-21
JP2003519476A (ja) 2003-06-24
NZ519671A (en) 2004-10-29
US6555342B1 (en) 2003-04-29
US20110229964A1 (en) 2011-09-22
AU2104301A (en) 2001-06-25
AU785283B2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
DE60044754D1 (de) Trans-lentivirales Vektor System
EP0873415A4 (de) Transfer system basierend auf einem fusionsprotein und seine anwendungen.
Ropers et al. Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
Li et al. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro
DE60303810D1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
YU150891A (sh) Rekombinantna genetska informacija
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
DE69732029D1 (de) Dna enthaltende impfstoffen
Nappi et al. Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap
DK1082423T3 (da) Cyclin E2-gener og -proteiner
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
PT871757E (pt) Vectores virais condicionalmente replicantes e sua utilizacao
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
ZA202300378B (en) Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
Lesner et al. Monoubiquitinated histone H1B is required for antiviral protection in CD4+ T cells resistant to HIV-1
Braddock et al. Orientation-specific cis complementation by bulge-and loop-mutated human immunodeficiency virus type 1 TAR RNAs
BR0114383A (pt) Interatuadores de canais de potássio e aplicações dos mesmos
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties